MindBio Therapeutics Begins Recruitment of Participants for World First LSD-Microdosing Clinical Trial in Cancer Patients Experiencing Emotional Distress

MindBio Therapeutics Corp. has recently started recruiting participants for an innovative clinical trial that combines LSD microdosing with Meaning Centred Psychotherapy to help cancer patients experiencing emotional distress. This groundbreaking trial aims to address the mental health needs of advanced stage cancer patients, making it the first of its kind in the world. &nbsp The Phase 2 trial ..

  • format_list_bulleted BS
  • · 2023. 7. 26.
  • textsms

SURGE Therapeutics Raises $32M Series B Financing to Advance Intraoperative Immunotherapy to Improve Cancer Patient Survival Outcomes Post-Surgery

SURGE Therapeutics, a biotech company headquartered in Cambridge, Massachusetts, has secured $32 million in Series B financing to advance its intraoperative immunotherapy programs. Leading the funding round is Bioluminescence Ventures, with participation from KdT Ventures, Piedmont Capital, and existing investors. &nbsp The raised funds will be utilized to support the clinical development of SUR..

  • format_list_bulleted BS
  • · 2023. 7. 19.
  • textsms

CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer

CEL-SCI Corporation recently had a productive meeting with the U.S. Food and Drug Administration (FDA) regarding the approval of Multikine for head and neck cancer treatment. The FDA recognizes the urgent need for better therapies in this field and is willing to collaborate with CEL-SCI to demonstrate the effectiveness of Multikine as a potential treatment option. Additionally, CEL-SCI is active..

  • format_list_bulleted BS
  • · 2023. 7. 16.
  • textsms

Quest Diagnostics Launches Novel Prostate Cancer Test Aimed at Improving Diagnosis and Grading

Quest Diagnostics has recently launched a groundbreaking prostate cancer test that aims to improve the diagnosis and grading of this disease. &nbsp This innovative lab service utilizes Envision Science's exclusive biomarkers and technology, with the ultimate goal of enhancing the accuracy of prostate cancer diagnosis and grading. The launch of this new test was announced by Quest Diagnostics, th..

  • format_list_bulleted BS
  • · 2023. 7. 14.
  • textsms

F-star Announces Strategic Collaboration and Licence Agreement with Takeda to Develop Next-Generation Multi-Specific Antibodies

F-star Therapeutics, an invoX company, has announced a strategic collaboration and license agreement with Takeda to discover and develop next-generation multi-specific antibodies. The collaboration will focus on using F-star's proprietary platforms to research and develop immunotherapies for cancer patients. Under the agreement, F-star and Takeda will work together to research and develop novel ..

  • format_list_bulleted BS
  • · 2023. 7. 6.
  • textsms

Immutep Completes A$80 Million Capital Raise

Immutep (Formerly known as Prima Biomed) Limited has successfully completed an A$80 million capital raise to support its clinical development pipeline. The company, a clinical-stage biotechnology firm specializing in LAG-3 immunotherapies for cancer and autoimmune diseases, believes that the new funding will fully support its current and expanded clinical program until Q1 CY2026. With a pro-form..

  • format_list_bulleted BS
  • · 2023. 6. 28.
  • textsms

Jubilant’s Precision Medicines Offer Safety, Therapeutic Advantages in Cancer, Immunology

Jubilant Therapeutics is preparing to begin Phase II and first-in-human trials later in 2023 with two Orphan Drug Designations, an advantageous safety profile, and enhanced therapeutic indices. The company's pipeline uses their Therapeutic Index and Brain Exposure Optimization (TIBEO) discovery engine to identify candidate molecules with improved therapeutic indices and the ability to penetrate ..

  • format_list_bulleted BS
  • · 2023. 6. 26.
  • textsms

Jubilant's Precision Medicines Offer Safety, Therapeutic Advantages in Cancer, Immunology

Jubilant Therapeutics, a precision oncology and immunology-focused biotech, is set to begin Phase II and first-in-human trials in 2023 with two Orphan Drug Designations. Their pipeline is generated entirely in-house using their unique discovery engine called the Therapeutic Index and Brain Exposure Optimization (TIBEO) which identifies candidate molecules with enhanced therapeutic indices that c..

  • format_list_bulleted BS
  • · 2023. 6. 23.
  • textsms

Jubilant’s Precision Medicines Offer Safety, Therapeutic Advantages in Cancer, Immunology

Jubilant Therapeutics is gearing up for Phase II and first-in-human trials in 2023 with its pipeline of precision medicines that offer safety and therapeutic advantages in cancer and immunology. The company's drug discovery approach focuses on developing candidates through clinical proof of concept, partnering those assets with companies to advance them through late-stage clinical development an..

  • format_list_bulleted BS
  • · 2023. 6. 22.
  • textsms

Jubilant’s Precision Medicines Offer Safety, Therapeutic Advantages in Cancer, Immunology

Jubilant Therapeutics is preparing for Phase II and first-in-human trials later in 2023, with two Orphan Drug Designations, an advantageous safety profile and enhanced therapeutic indices. The company's pipeline is generated 100% in-house using its Therapeutic Index and Brain Exposure Optimization (TIBEO) discovery engine, which permits the identification of candidate molecules with enhanced the..

  • format_list_bulleted BS
  • · 2023. 6. 20.
  • textsms